The Transform trial’s expansion introduces three critical changes to prostate cancer screening practice. First, black men now begin screening at age 50 rather than 60, reflecting evidence that earlier detection is warranted in higher-risk populations. Second, the trial acknowledges fundamental limitations of PSA blood testing alone—studies show it misses approximately 15% of cancers while generating 70% false positives, creating unnecessary anxiety and follow-up procedures. Third, the new protocol combines PSA testing with MRI imaging to improve diagnostic accuracy and reduce harms. These practical improvements matter for patients and clinicians. For black men aged 50-69, discussion with healthcare providers about individual risk factors and screening options is now particularly relevant. The trial represents a shift toward personalized, risk-stratified screening that accounts for both biological differences and documented health inequities. Read the full article on GMJ Newsroom.
Was this article helpful?
